• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors

    12/14/20 4:05:00 PM ET
    $TNDM
    $RMD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email

    SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi as an independent member of its board of directors effective January 1, 2021. He will succeed Edward Cahill, who has served as a board member for the Company since May 2009. Mr. Sodhi is president of the software as a service (SaaS) business at ResMed (NYSE: RMD, ASX: RMD). He brings to the Tandem board more than 25 years of digital strategy experience, SaaS commercialization and operations across multiple industries including healthcare, financial services, and telecom.

    “We are pleased to welcome Raj to our Board of Directors at this important next stage of Tandem’s evolution,” said John Sheridan, president and chief executive officer. “Raj’s deep experience in driving innovation through software technologies will be invaluable to Tandem as we grow our business and advance our ecosystem of data-driven products and services in support of improving the lives of people with diabetes.”

    “I’d like to express our deep appreciation to Ed for his contributions as a member of our Board over the past 11 years,” said Kim Blickenstaff, chairman of the board. “He has provided valuable insight and support at every stage of our company as we transformed from a small start-up to a leader in insulin therapy management.”

    Mr. Sodhi joined ResMed in 2012 through the acquisition of Umbian Inc., of which he was co-founder and president. Since that time, Mr. Sodhi has served in several positions at ResMed including President of Healthcare Informatics where he led the creation of ResMed’s portfolio of digital solutions that connects more than 12 million patients globally to ResMed’s ecosystem of cloud-connected medical devices and digital health technologies that have transformed care for people with sleep apnea, COPD, and other chronic diseases. Since 2016, Mr. Sodhi has led a series of healthcare IT acquisitions focused on software platforms serving providers outside of the hospital and building a new segment of growth for ResMed that represents 12 percent of ResMed’s global revenues and enables providers across the United States to serve more than 100M+ patients and residents.

    Before ResMed and Umbian, Mr. Sodhi worked in the financial services industry, designing, developing and managing SaaS solutions. He was senior vice president of business development and chief technology officer for Skipjack Financial Services, and co-founder and chief technology officer of TransActive Ecommerce Solutions. Mr. Sodhi holds a Master of Business Administration and a Bachelor of Science in mathematics and statistics from Dalhousie University in Halifax, Nova Scotia.

    About Tandem Diabetes Care, Inc.

    Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

    Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

    Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
    Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
    Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

    Get the next $TNDM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNDM
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    ResMed Inc.
    $RMD
    9/18/2025$330.00Buy
    Citigroup
    Tandem Diabetes Care Inc.
    $TNDM
    9/8/2025$22.00Outperform
    Oppenheimer
    ResMed Inc.
    $RMD
    9/2/2025Hold → Outperform
    CLSA
    Tandem Diabetes Care Inc.
    $TNDM
    8/12/2025$10.35Sell → Neutral
    Citigroup
    Tandem Diabetes Care Inc.
    $TNDM
    8/7/2025$14.00Overweight → Neutral
    Piper Sandler
    ResMed Inc.
    $RMD
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    ResMed Inc.
    $RMD
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    Tandem Diabetes Care Inc.
    $TNDM
    7/9/2025$14.00Neutral → Sell
    Citigroup
    More analyst ratings

    $TNDM
    $RMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Sheridan John F bought $102,318 worth of shares (10,000 units at $10.23), increasing direct ownership by 10% to 106,327 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 6:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought $149,404 worth of shares (13,720 units at $10.89) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 5:18:51 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    3/11/25 6:06:01 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States

    Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.). "This latest milestone reinforces our commitment to facilitating choice and access for people who rely on insulin therapy," said Jordan Pinsker, MD, Chief Medical Officer at Tandem Diabetes Care. "This clearance allows people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes to use Lyumjev with the t:slim X2 i

    9/29/25 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025

    SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days. About ResmedResmed (NYSE:RMD, ASX: R

    9/16/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels

    This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and Medicaid Services (CMS) criteria for insulin pump coverage. Tandem Diabetes Care® (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced the publication of a study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," in the American Diabetes Association's Diabetes Care. The study, a sub-analysis from the 2IQP randomized, controlled trial, found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insulin-treated type 2 diabetes, regardless

    9/16/25 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on ResMed with a new price target

    Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00

    9/18/25 8:44:39 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Tandem Diabetes Care with a new price target

    Oppenheimer initiated coverage of Tandem Diabetes Care with a rating of Outperform and set a new price target of $22.00

    9/8/25 8:59:21 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by CLSA

    CLSA upgraded ResMed from Hold to Outperform

    9/2/25 11:05:47 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    2/4/25 9:15:00 AM ET
    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $TNDM
    $RMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Financials

    Live finance-specific insights

    View All

    Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance. Second Quarter 2025 Highlights Achieved record second quarter sales both in the United States (U.S.) and internationally. Demonstrated year-over-year and sequential gross margin improvement. Initiated an early access program for the t:slim X2™ insulin pump with Control-IQ+ technology integrated with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor in the U.S. Progressed multichannel initiative to include t:slim X2 supplies as a pharmacy benefit beg

    8/6/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

    7/31/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

    SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, July 31, 2025, 9:30 p.m. BSTSydney, Friday, August 1, 2025, 6:30 a.m. AEST     Please note, Resmed

    7/1/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    SEC Filings

    View All

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    8/18/25 4:20:28 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by ResMed Inc.

    10-K - RESMED INC (0000943819) (Filer)

    8/7/25 8:44:48 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Other Events

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    8/7/25 4:09:32 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    9/9/24 10:40:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tandem Diabetes Care Inc.

    SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

    2/14/24 7:37:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 207 shares, increasing direct ownership by 0.89% to 22,566 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    9/16/25 4:47:14 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,415 shares and covered exercise/tax liability with 3,866 shares, increasing direct ownership by 12% to 32,348 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    9/16/25 4:47:08 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $2,227,590 worth of ResMed Common Stock (8,009 units at $278.14) (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    9/9/25 4:10:04 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care